argenx Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de argenx de 56.1% y 24.7% por año respectivamente. Se prevé que el BPA crezca en un 53.3% al año. Se espera que la rentabilidad financiera sea de 13.5% en 3 años.

Información clave

56.1%

Tasa de crecimiento de los beneficios

53.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.5%
Tasa de crecimiento de los ingresos	24.7%
Rentabilidad financiera futura	13.5%
Cobertura de analistas	Good
Última actualización	26 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

BATS-CHIXE:ARGXB - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	3,219	784	362	523	22
12/31/2025	2,451	234	240	198	28
12/31/2024	1,799	-146	-74	-283	29
12/31/2023	1,269	-295	-464	-420	N/A
9/30/2023	1,029	-234	N/A	N/A	N/A
6/30/2023	835	-397	-758	-654	N/A
3/31/2023	639	-511	N/A	N/A	N/A
12/31/2022	441	-710	-967	-863	N/A
9/30/2022	286	-909	N/A	N/A	N/A
6/30/2022	146	-907	-874	-876	N/A
3/31/2022	381	-595	N/A	N/A	N/A
12/31/2021	528	-408	-728	-607	N/A
9/30/2021	510	-373	N/A	N/A	N/A
6/30/2021	526	-319	-601	-474	N/A
3/31/2021	206	-573	N/A	N/A	N/A
12/31/2020	62	-608	-404	-398	N/A
9/30/2020	75	-535	N/A	N/A	N/A
6/30/2020	70	-359	-263	-255	N/A
3/31/2020	73	-275	N/A	N/A	N/A
12/31/2019	93	-181	105	152	N/A
9/30/2019	72	-109	N/A	N/A	N/A
6/30/2019	68	-104	188	230	N/A
3/31/2019	70	-47	N/A	N/A	N/A
12/31/2018	33	-76	-62	-62	N/A
9/30/2018	41	-56	N/A	N/A	N/A
6/30/2018	44	-47	-57	-57	N/A
3/31/2018	50	-46	N/A	N/A	N/A
12/31/2017	49	-34	-44	-44	N/A
9/30/2017	42	-30	N/A	N/A	N/A
6/30/2017	39	-25	N/A	-31	N/A
3/31/2017	23	-29	N/A	N/A	N/A
12/31/2016	18	-22	N/A	11	N/A
9/30/2016	17	-20	N/A	N/A	N/A
6/30/2016	14	-17	N/A	16	N/A
3/31/2016	12	-17	N/A	N/A	N/A
12/31/2015	11	-17	N/A	-15	N/A
9/30/2015	10	-16	N/A	N/A	N/A
6/30/2015	9	-14	N/A	-10	N/A
3/31/2015	7	-12	N/A	N/A	N/A
12/31/2014	7	-12	N/A	-6	N/A
9/30/2014	6	-10	N/A	N/A	N/A
6/30/2014	7	-8	N/A	-6	N/A
3/31/2014	7	-9	N/A	-8	N/A
12/31/2013	7	-8	N/A	-9	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ARGXB sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (1.6%).

Beneficios vs. Mercado: Se prevé que ARGXB sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que ARGXB sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (24.7% al año) de ARGXB crezcan más rápidamente que los del mercado UK (3.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (24.7% al año) de ARGXB crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de ARGXB sea baja dentro de 3 años (13.5%).

argenx Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2025

Recent updates

argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease

Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Full year 2023 earnings released: US$5.16 loss per share (vs US$13.05 loss in FY 2022)

argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE Announces Approval of VYVDURA (efgartigimod Alfa and Hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

argenx SE, Annual General Meeting, May 07, 2024

CEO & Executive Director recently sold €1.0m worth of stock

argenx SE Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

argenx SE Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

argenx SE Announces European Commission Approval of Subcutaneous VYVGART (efgartigimod alfa) for Generalized Myasthenia Gravis

Argenx Se Announces 20 Presentations of Clinical Trial and Real-World Data from Studies of Vyvgart® and Vyvgart Hytrulo® (Vyvgart) in Neuromuscular Autoimmune Disease

Third quarter 2023 earnings released: US$1.25 loss per share (vs US$4.26 loss in 3Q 2022)

Independent Chairman of the Board recently sold €3.8m worth of stock

Argenx Announces VYVGART (Efgartigimod Alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

CEO & Executive Director recently sold €1.9m worth of stock

Second quarter 2023 earnings released: US$1.69 loss per share (vs US$3.81 loss in 2Q 2022)

argenx SE to Report Fiscal Year 2023 Results on Feb 29, 2024

New minor risk - Shareholder dilution

New minor risk - Share price stability

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

argenx SE Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo Injection for Subcutaneous Use in Generalized Myasthenia Gravis

Now 21% undervalued

First quarter 2023 earnings released: US$0.52 loss per share (vs US$4.36 loss in 1Q 2022)

Full year 2022 earnings released: US$13.05 loss per share (vs US$7.99 loss in FY 2021)

argenx SE Receives Notification of PDUFA Date Extension for SC Efgartigimod

argenx SE Announces Werner Lanthaler Will Resign as Non-Executive Director of Board and Chair of Audit and Compliance Committee

Forecast to breakeven in 2025

argenx SE Appoints Ana Cespedes as Non-Executive Director to Its Board of Directors

argenx SE Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review

Insufficient new directors

argenx SE Announces the Retirement of Hans De Haard as Chief Scientific Officer

Third quarter 2022 earnings released: US$4.26 loss per share (vs US$4.10 loss in 3Q 2021)

argenx SE to Report Q3, 2023 Results on Oct 27, 2023

argenx SE Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis

argenx Appoints Camilla Sylvest to Board of Directors

Argenx Announces European Commission Approval of VYVGART(TM) (Efgartigimod Alfa-Fcab) for the Treatment of Generalized Myasthenia Gravis

Second quarter 2022 earnings released: US$3.81 loss per share (vs US$2.02 profit in 2Q 2021)

argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe

argenx SE Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases

First quarter 2022 earnings released: US$4.36 loss per share (vs US$0.81 loss in 1Q 2021)

argenx SE Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

Insufficient new directors

Argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART (Efgartigimod Alfa-Fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting

argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting

argenx SE, Annual General Meeting, May 10, 2022

argenx SE, Annual General Meeting, May 10, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

argenx SE to Report Q3, 2022 Results on Oct 27, 2022

argenx SE to Report Q4, 2021 Results on Mar 03, 2022

argenx Announces VYVGART Approval in Japan for the Treatment of Generalized Myasthenia Gravis

Independent Non-Executive Director recently sold €2.3m worth of stock

Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

Third quarter 2021 earnings released: US$4.10 loss per share (vs US$3.92 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS US$2.02 (vs US$3.09 loss in 2Q 2020)

Chief Financial Officer Eric Castaldi has left the company

argenx Announces Publication of Phase 3 ADAPT Trial Results of Efgartigimod for the Treatment of Generalized Myasthenia Gravis in the Lancet Neurology

First quarter 2021 earnings released: US$0.81 loss per share (vs US$2.06 loss in 1Q 2020)

Full year 2020 earnings released: €11.65 loss per share (vs €4.22 loss in FY 2019)

Full year 2020 earnings released: €11.65 loss per share (vs €4.22 loss in FY 2019)

Revenue misses expectations

argenx SE Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis

New 90-day high: €310

argenx Issues Statement Concerning Efgartigimod

argenx SE Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis

New 90-day high: €255

argenx Announcea Interim Data from the Phase 2 Culminate Trial of cusatuzumab in Development with Cilag GmbH International

argenx SE and Zai Lab Limited Announce an Exclusive License Agreement for the Development and Commercialization of efgartigimod in Greater China, Including Mainland China, Hong Kong, Taiwan and Macau

New 90-day high: €240

argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience

argenx Announces Partnership with Chugai and the Clayton Foundation

argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session

Previsiones de crecimiento de beneficios e ingresos